



Not for distribution or release in the United States

ASX ANNOUNCEMENT

18 October 2021

Close of Share Purchase Plan Offer

18 October 2021 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce the close on Friday, 15 October 2021, of the share purchase plan offer (**SPP Offer**) that was announced on Tuesday, 7 September 2021. The SPP Offer is being undertaken to provide funds to invest in initiatives which are expected to deliver substantial cost savings as Cann moves to large scale production with the commissioning of its new manufacturing facility near Mildura.

The Company will release the results of the SPP Offer on Thursday, 21 October 2021.

Further information

For further information regarding the SPP Offer, please contact Cann's Share Registry, Link Market Services Limited between 8.30am and 5.30pm (Melbourne time), Monday to Friday on the following numbers:

Tel: 1300 363 917 (within Australia)

Tel: +61 1300 363 917 (outside Australia)

Authorised for release by the Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420

matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088

contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088

clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com